X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This partnership will leverage Pharmapark’s strong local presence, sales and marketing capabilities in Russia and other CIS countries. Bio-Thera will be responsible for full development, and commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou, China.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: BAT2206
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Bio-Thera Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 16, 2021
Details:
The partnership arrangement includes the exclusive rights for Pharmapark to commercialize the Bevacizumab biosimilar in the Russian Federation, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market.
Lead Product(s): Bevacizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: HD204
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Prestige BioPharma Pte Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2021
Details:
Bio-Thera has reached a licensing agreement with Pharmapark LLC, for BAT2506, its golimumab biosimilar, under which Pharmapark will have exclusive rights to distribute and market the drug with a status of a local product in Russia and other CIS countries.
Lead Product(s): Golimumab
Therapeutic Area: Immunology Product Name: BAT2506
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pharmapark
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
